Skip to content
Search

Latest Stories

'East England ranks 5th in nation for quitting smoking', new study shows

'East England ranks 5th in nation for quitting smoking', new study shows

Study suggests vaping as "a less harmful alternative" to smoking cigarettes 

A recent study conducted by online vape store GoSmokeFree using data from the NHS Stop Smoking Service in England between April to September 2023 has revealed the regions across the UK with the highest success rates in quitting smoking.


According to the data analysis, the East of England emerges as the fifth most successful region in the UK for smoking cessation while the Isle of Wight in the South East region with 3,124 people quitting per 100,000 smokers were the most successful at quitting smoking.

The study ranked regions based on the average number of successful quitters per 100,000 smokers. The South East takes the lead, followed by the North East and the North West. The East of England secured the fifth spot with an average of 981 smokers per 100,000 successfully quitting smoking during the designated period.

Southend-on-Sea emerges as the most successful area within the East of England, boasting 1,591 smokers per 100,000 who have managed to kick the habit.

However, the data also reveals that out of 3,032 smokers who set a quit date in this region, 834 were unable to quit within the specified timeframe.

The study further breaks down the success rates by local authority areas within each region. For instance, in Lincolnshire, the most successful area within the East Midlands, 1,274 smokers per 100,000 have successfully quit out of 2,123 who set a quit date. Similarly, Gateshead in the North East and Sefton in the North West show notable success rates.

Notably, while the South West ranked the lowest amongst the regions to successfully stop smoking with only an average of 599 smokers per 100,000 giving up smoking, Cornwall has emerged with the most self-proclaimed quitters with 955 per 100,000 in total.

A spokesperson from GoSmokeFree commented on the findings, emphasizing the challenges associated with quitting smoking due to nicotine withdrawals and mental hurdles leading to long-term health issues including lung cancer and gum diseases.

The spokesperson highlighted various methods to assist individuals in their journey to quit smoking, including keeping a smoking diary, quitting cold turkey, and transitioning to vaping as a less harmful alternative.

The study underscores the importance of continued efforts to support smoking cessation initiatives across regions for improving overall health outcomes and reducing the burden of smoking-related illnesses.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less